HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Goldstein S, Krallman KA, Kirby CL, et al.

Outcomes from the Use of the Selective Cytopheretic Device (SCD) in Critically Ill Children Receiving CRRT: A Report of the Multicenter Pediatric SCD (pSCD) Study

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:16A 2020

BACKGROUND

Critically ill children who develop acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) are at increased risk of death. The SCD promotes an immunomodulatory effect in a hypocalcemic environment (ionized Ca (ionCa) < 0.4 mmol/L) in animal models of inflammation. In a randomized trial, adult ICU patients on CRRT treated with the SCD, who maintained CRRT ionCa < 0.4 mmol/L, had improved survival/dialysis independence. We conducted an FDA grant sponsored safety evaluation (adverse and serious adverse events) of the SCD in 16 critically ill children.

METHODS

4 center US study of the SCD in children (>15 kg, ≤22 years) with AKI and multiorgan failure receiving CRRT. The SCD was integrated post CRRT membrane, changed daily, and circuit ionCa maintained <0.4 mmol/L. Pts received SCD treatment for up to 7 days or CRRT discontinuation.

RESULTS

16 pts (8F/8M) completed the study from 12/2016 thru 2/2020. Mean pt age was 12 yr (range 4-21 yr), weight was 53 kg (range 19-111 kg) and PRISM 2 score was 7 (range 2-19). Two pts received ECMO. The most common ICU diagnosis was shock. Circuit ionCa were maintained at <0.4 mmol/L for 90.2% of assessments. Median SCD duration was 6 days (range 1 to 7). 15/16 pts survived SCD therapy, 12/16 patients survived to ICU discharge. All 12 ICU survivors were dialysis independent at 60 days. No SCD related adverse events were noted.

CONCLUSION

Our data suggest the SCD is safe in critically ill children who require CRRT. While we cannot make efficacy claims, the 75% survival rate and 100% renal recovery rate in surviving children suggest a favorable benefit to risk ratio.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.